Abstract:Background Clinical outcomes of patients with glioma are still poor, even after standard treatments, including surgery combined with radiotherapy and chemotherapy. New therapeutic strategies and targets for glioma are urgently needed. Plasminogen activator urokinase receptor (PLAUR), a highly glycosylated integral membrane protein, is reported to modulate plasminogen activation and extracellular matrix degradation in many malignant cancers, but its role in gliomas remains unclear.Methods Glioma samples with mRNA sequencing data and clinical information from the Chinese Glioma Genome Atlas (n = 310) data set and The Cancer Genome Atlas (n = 611) data set were collected for this study. Analyses using Kaplan-Meier plots, time-dependent receiver operating characteristic curves, Cox regression, and nomograms were conducted to evaluate the prognostic performance of PLAUR expression. Analyses using Metascape, ESTIMATE, EPIC, and immunohistochemical staining were performed to reveal the potential biological mechanism. The statistical analysis and graphical work were completed using SPSS, R language, and GraphPad Prism.Results PLAUR was highly expressed in phenotypes associated with glioma malignancy and could serve as an independent prognostic indicator. Functional analysis revealed the correlation between PLAUR and immune response. Further studies found that samples with higher PLAUR expression were infiltrated with fewer CD8 T cells and many more M2 macrophages. Strong positive correlation was demonstrated between PLAUR expression and some immunosuppressive markers, including immune checkpoints and cytokines. These findings were also confirmed in patient samples.Conclusion Our results elucidated the clinical significance and immunosuppressive effect of PLAUR in gliomas, which might provide some clues in glioma immunotherapy.Implications for Practice Although the efficacy of immunotherapy has been verified in other tumors, its application in glioma is impeded because of the unique microenvironment. Tumor-associated macrophages, which are particularly abundant in a glioma mass, contribute much to the immunosuppressive microenvironment and offer new opportunities in glioma immunotherapy. The results of this study identified plasminogen activator urokinase receptor (PLAUR) expression as a potential marker to predict the infiltration of macrophages and the status of immune microenvironment in patients with glioma, suggesting that treatment decisions could be based on PLAUR level when administering immunotherapeutics. The soluble PLAUR in blood and other body fluids would make this approach easy to implement in the clinic.

Prognostic Significance and Gene Co-Expression Network of <i>PLAU</i> and <i>PLAUR</i> in Gliomas

Plasminogen Activator Urokinase Receptor Implies Immunosuppressive Features And Acts As An Unfavorable Prognostic Biomarker In Glioma

Overexpressed PLAU and Its Potential Prognostic Value in Head and Neck Squamous Cell Carcinoma.

Combination of Theoretical Analysis and Experiments: Exploring the Role of PLA2G7 in Human Cancers, Including Renal Cancer

PLAU Promotes Cell Proliferation and Epithelial-Mesenchymal Transition in Head and Neck Squamous Cell Carcinoma

Effect of urokinase-type plasminogen activator combined with clinical stage and Barcelona Clinic Liver Cancer stage on the prognosis of patients with hepatocellular carcinoma

Expression and Localisation of Urokinase-Type Plasminogen Activator Gene in Gliomas

Overexpression of the phospholipase A2 group V gene in glioma tumors is associated with poor patient prognosis.

Expression and Significance of Urokinase-Type Plasminogen Activator in Human Gliomas.

Pan-cancer Analysis of PLAU Indicates Its Potential Prognostic Value and Correlation with Neutrophil Infiltration in BLCA.

PLAU, transcriptionally negatively regulated by GATA6, promotes lung squamous carcinoma cell proliferation and migration

Hypomethylation and downregulation of miR-23b-3p are associated with upregulated PLAU: a diagnostic and prognostic biomarker in head and neck squamous cell carcinoma

PLAU and LAMC2 can predict a poor prognosis in patients with HNSCC

FOXM1 Functions Collaboratively with PLAU to Promote Gastric Cancer Progression

An Inflammatory Gene-Related Prognostic Risk Score Model for Prognosis and Immune Infiltration in Glioblastoma.

Identifying PLAUR as a Pivotal Gene of Tumor Microenvironment and Regulating Mesenchymal Phenotype of Glioblastoma

Comprehensive Analysis of the Importance of PLAUR in the Progression and Immune Microenvironment of Renal Clear Cell Carcinoma

Prognostic significance and gene co-expression network of CD16A and FGL2 in gliomas

Correlation of Expression Levels of ANXA2, PGAM1, and CALR with Glioma Grade and Prognosis.

PLAU contributes to the development of cholangiocarcinoma via activating NF‐κB signaling pathway

Prognostic Markers Identification in Glioma by Gene Expression Profile Analysis